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Abstract 
Background 
Massive bleeding is a major cause of death both in trauma and non-trauma patients. In trauma 
patients, the implementation of massive transfusion protocols (MTP) led to improved outcomes. 
However, the majority of patients with massive bleeding are non-trauma patients. 
Objectives 
To assess if the implementation MTP in non-trauma patients with massive bleeding leads to 
improved survival. 
Data sources 
National Library of Medicine’s Medline database (PubMed). 
Study eligibility criteria 
Original research articles in English language investigating MTP in non-trauma patients. 
Participants 
Non-trauma patients with massive bleeding  18 years of age. 
Intervention 
Transfusion according to MTP versus off-protocol. 
Study appraisal and synthesis methods 
Systematic literature review using PubMed. Outcomes assessed were mortality and transfused 
blood products. Studies that compared mortality of MTP and non-MTP groups were included in 
meta-analysis using Mantel-Haenszel random effect models. 
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Results 
A total of  252 abstracts were screened. Of these, 12 studies published 2007-2017 were found to 
be relevant to the topic, including 2,475 patients. All studies were retrospective and comprised 
different patient populations. Most frequent indications for massive transfusion were 
perioperative, obstetrical and gastrointestinal bleeding, as well as vascular emergencies. Four out 
of the five studies that compared the number of transfused blood products in MTP and non-MTP 
groups revealed no significant difference. Meta-analysis revealed no sigificant effect of MTP on 
the 24-hour mortality (OR 0.42, 95%CI 0.01-16.62, p=0.65) and a trend towards lower one-
month mortality (OR 0.56, 95%CI 0.30-1.07, p=0.08). 
Limitations 
Heterogeneous patient populations and MTP in the studies included. 
Conclusions and implications of key findings 
There is limited evidence that the implementation of MTP may be associated with decreased 
mortality in non-trauma patients. However, patient characteristics, as well as the indication and 
definition of MTP were highly hetergenous in the available studies. Further prospective 
investigation into this topic is warranted. 
Study type 
Systematic review and meta-analysis 
Level of evidence 
Level III 
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Background 
In patients receiving massive transfusion a high mortality rate has been described, both in the 
trauma and non-trauma setting.(1-3) Rose et al. report an in-hospital mortality rate of 34% in a 
mixed patient population receiving massiv transfusion.(2) Halmin et al., in a nationwide cohort 
study assessing the epidemiology of massive transfusion in Sweden and Denmark, report a 30-
day mortality of 24.8%.(1) Turan et al. investigated the mortality after massive transfusion in 
patients undergoing non-cardiac surgery using the American College of Surgeons National 
Surgical Quality Improvement Program (NSQIP) database. In this study, a postoperative 30-day 
mortality of 17% was found in patients undergoing massive transfusion.(3) Common causes for 
massive hemorrhage in non-trauma patients are gastrointestinal bleeding, ruptured abdominal 
aortic aneurisms, as well as surgical or obstetrical bleeding.(4-7) In the above-mentioned cohort 
study conducted in Sweden and Denmark, massive transfusion was reported with an incidence of 
2.5 (Sweden) and 4.5 (Denmark) per 10,000 person years.(1) Turan et al. report massive 
transfusion in 7,485 out of 917,651 patients in NSQIP 2006-2009, corresponding to 0.8%.(3) 
Most recent studies investigating the pathophysiology and treatment of hemorrhage focused on 
trauma patients.(4, 6-11) However, major surgery for non-traumatic disease has been reported to 
be the most common cause of massive bleeding, followed by trauma and obstetric bleeding. 
Although the overall incidence of massive bleeding is relatively small, it remains an important 
source of mortality in non-trauma patients.(1, 3) 
The goal of massive transfusion protocols (MTP) is to rapidly provide blood products to 
hemodynamically unstable bleeding patients and to treat coagulopathy. This includes the 
availability of blood products in predefined ratios and the rapid transport and transfusion of these 
products.(12) MTP have been successfully implemented in trauma patients and have been shown 
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to improve outcomes in this patient population(12), including lower mortality(13), a lower risk 
of multi-organ failure, higher rate of fascial closure(14), and decreased use of blood 
products(15). The current guidelines of the American College of Surgeons Trauma Quality 
Improvement Program (ACS TQIP), support the implementation of MTP in the early care of 
trauma patients.(16) 
In sumary, massive transfusion is rare but associated with a high mortality rate in non-trauma 
patients. Taking into account the above-mentioned improved outcomes related to MTP in trauma 
patients, non-trauma patients may benefit from MTP, too. The aim of this systematic review and 
meta-analysis was, therefore, to assess the use MTP and its effect on outomes in non-trauma 
patients. We hypothesized that the implementation MTP in non-trauma patients with massive 
bleeding leads to improved survival. 
 
Methods 
This is a systematic literature review and meta-analysis investigating the role of MTP in bleeding 
non-trauma patients. PRISMA guidelines(17, 18) were followed thoughout the literature search, 
meta-analysis, reporting of the data, and discussion. (Table 5) 
 
Literature search 
A systematic literature search was conducted using the National Library of Medicine's Medline 
database (PubMed)(19). The search strategy was based on the PICOS process.(20, 21) When 
possible, Medical Subject Headings (MeSH)(22) were used as search terms. The following 
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search terms were used for the PubMed search: 
 massive AND transfusion AND protocol AND (surgical OR medical) 
 massive AND transfusion AND protocol AND (surgical OR medical); Filters: review 
 (((blood transfusion) AND exchange transfusion, whole blood) AND surgical procedures, 
operative) AND patient care 
 (((blood transfusion[MeSH Terms]) AND exchange transfusion, whole blood[MeSH 
Terms]) AND surgical procedures, operative[MeSH Terms]) AND patient care[MeSH 
Terms] 
 massive transfusion protocol AND (surgical procedures, operative OR patient care) 
Only original research articles in english language were included. Exclusion criteria were articles 
including patients under 18 years of age and non-original research articles such as literature 
reviews and letters to the editor. 
All abstracts of the articles found were screened. If the abstracts were relevant to the topic, the 
corresponding articles were included in the review. Articles relevant to the topic that were cited 
in articles found on PubMed using the above-named search terms were also included in the 
review, as well as articles that described MTP both trauma and non-trauma patients. 
 
Quality assessment 
The quality of the studies included in this systematic literature review and meta-analysis was 
assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies (23) with mortality as 
outcome measure. 
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Outcomes 
The primary outcome assessed was the 24-hour and one-month mortality. Secondary outcomes 
were the number of blood products transfused, including packed red blood cells (PRBC), fresh 
frozen plasma (FFP), and platetelts, as well as transfusion ratios. 
 
Statistical analysis 
Studies that compared the mortality rate of MTP and non-MTP groups in non-trauma patients 
specifically were included in the meta-analysis. The number of survivors and non-survivors in 
MTP and non-MTP groups reported in these studies was extracted for the meta-analysis. 
Meta-analysis for the 24-hour and one-month mortality was performed using a Mantel-Haenszel 
random effect model. The estimated effect size for the 24-hour and one-month mortality was 
reported as odds ratio (OR) and 95% confidence interval (CI) for each study that compared MTP 
and non-MTP groups, as well as for the overall cohort. Heterogeneity of included studies was 
assessed using cochran's Q statistic and I
2
.(24, 25) No funnel plots were created due to the small 
number of studies included in meta-analysis. 
Statistical analysis was performed using Review Manager (RevMan) Version 5.3. (Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
Results 
Articles included 
The literature search and included articles are outlined in Figure 1. A total of  252 abstracts were 
screened. Twelve articles were found to be relevant to the topic.(4-11, 26-29) All articles were 
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published between 2007 and 2017. Included studies enrolled a total of 2,475 patients. Of these, 
1,620 were non-trauma patients. (Table 1) 
Seven studies included both trauma and non-trauma patients.(4-7, 9, 10, 29) The non-trauma 
groups in these studies were comprised of patients undergoing emergency or elective surgery(4-
10, 29), as well as patients with gastrointestinal bleeding(4-7, 9, 29), obstetric hemorrhage(4, 5, 
7, 10, 29), and vascular emergencies(4, 6, 7, 9, 29). In three of these seven studies, analysis was 
performed using a mixed trauma/non-trauma population, comprising 91%(10), 76%(29), and 
38.2-100% (range, six hospitals included)(5) non-trauma patients. In four studies, trauma and 
non-trauma patients were analyzed separaterly.(4, 6, 7, 9) (Table 1) 
Five studies investigated non-trauma patients only.(8, 11, 27) (26, 28) Three studies focused on 
patients with bleeding due to obstetric complications only(11, 26, 27), whereas Johansson et al. 
analyzed patients with massive bleeding after ruptured abdominal aortic aneurysm 
exclusively.(28) Martinez-Calle et al. included non-trauma patiens undergoing oncolocic 
surgery, cardiovascular surgery, other surgery, and non-surgical treatment for massive 
bleeding.(8) 
 
Quality assessment 
Table 4 shows the quality assessment of the studies included based on the NOS. None of the 
studies included used a matched study desing or adjusted for counfounders. Therefore, based on 
the criteria of the NOS, no study received stars for the comparability of the study groups. The 
studies by Chay(5), Gutierrez(27), and Goodnough(26) did not receive stars for the outcome 
categories, as mortality was not reported as an outcome measure in these studies. Furthermore, 
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the studies by Gutierrez and Goodnough did not include a controll group and consequently did 
not recieve a star in this category. In the studies by Chay(5) and Johanson(28) the number of 
survivors and death was not reported. These studies therefore did not receive stars for the 
adequacy of follow-up category. 
 
Patient characteristics 
The majority of the patients included were male, ranging from 64.4 to 87.1%.(4, 6-10, 28) 
Exceptions were the studies assessing obstetric patients only.(11, 26, 27) The age of included 
patients ranged from 29.9 to 73.0 years. (Table 1) 
Three studies reported comorbidities of the patients included.(4, 10, 28) Balvers et al. showed 
that 26% of patients before the introduction of a MTP and 25% of the patients after the 
introduction had no known comorbidities. The remaining patients suffered from cardiovascular 
(57% in both groups) or pulmonary disease (8% and 7%), bleeding diathesis (4% and 3%), and 
other comorbidities (5% and 8%).(10) Johansson et al. found comorbidities in 74% and 73% of 
patients before and after the implementation of a MTP, respectively.(28) In the study by 
Baumann Kreuziger et al. the mean overall APACHE II score was 27, while it was significantly 
lower in trauma than in non-trauma patients (25 vs. 29, p<0.05).(4) The other studies did not 
report comorbidities of included patients.(5-9, 11, 26, 27, 29) 
Definition of massive transfusion 
The definition of massive transfusion was given in 9 articles. (4-11, 29) Massive transfusion was 
most commonly defined as the transfusion of 10 or more units of PRBC in the first 24 hours after 
hospital admission.(4-7, 9, 29) Other definitions were the transfusion of 5 or more units of PRBC 
AC
CE
PT
ED
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
11 
 
in the first twelve hours after hospital admission(10), the replacement of the whole blood volume 
(7% of ideal body weight in adults) in a 24 hour period (8), the replacement of 50% of the whole 
blood volume in a three hour period(8), the loss of ≥ 1500 ml blood in ten minutes(8), or the 
transfusion of 4 or more units of PRBC.(11) 
 
Indications for massive transfusion 
Indications for massive transfusion in non-trauma patients were bleeding during or after surgery 
(frequency reported as 11.2 to 82.2%)(4-10, 29), obstetrical bleeding (4.4 to 100%)(4, 5, 7, 10, 
11, 26, 27, 29), gastrointestinal bleeding (20.0 to 66.7%)(4-7, 9, 29), vascular emergencies (2.7 
to 100%)(4, 6, 7, 9, 28, 29), or other reasons (13.0 to 17.8%).(4, 8, 10) 
 
Blood product transfusion 
Transfused blood products are shown in Table 2. Of the five studies that compared the number of 
transfused units of blood products in non-trauma patients before and after the implementation of 
a MTP(6, 8, 10, 11, 28), four studies revealed no statistically significant difference of the number 
of transfused units of PRBC, FFP, and PLT.(6, 8, 10, 11) In the study investigating the 
implemantation of a transfusion protocol in patients with ruptured abdominal aortic aneurysms, a 
significantly higher number of FFP and PLT during surgery, but lower postoperative transfusion 
of PRBC, FFP and PLT were found after implementation of the protocol.(28) 
Transfusion ratios (FFP:PRBC, PLT:PRBC) were reported in 9 studies.(4-11, 29) Of these, five 
studies compared transfusion ratios in MTP and non-MTP groups.(6, 8, 10, 11, 29) Sinha et al. 
reported significantly higher FFP:PRBC and PLT:PRBC transfusion ratios in the MTP group 
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compared to the Pre-MTP group.(29) In the study by Balvers et al. a significantly higher 
proportion of patients in the MTP-group received PRBC:FFP transfusion ratios ≤ 1.1 compared 
to the Pre-MTP group.(10) In the other 3 studies, no statistically significant difference of the 
transfusion ratios in the MTP and non-MTP groups was found.(6, 8, 11) (Table 2) 
Overactivation of MTP, defined as the proportion of patients with MTP activation that received 
≤ 10 units of PRBC, was reported in four studies. The rate of MTP overactivation found in these 
studies was high, ranging from 53.8% to 65%.(4, 6, 7, 9) (Table 2) 
McDaniel et al. analyzed the wasted units of blood products before and after the implementation 
of a MTP. A significantly increased waste of platelets was observed in patients with MTP 
activation compared to patients without MTP activation (12.8% vs. 8.1%, p=0.046).(6) 
 
Impact of MTP on mortality 
Four studies compared the one-month mortality in patients with and without MTP activation(6, 
8, 10, 28) Of these four studies, two studies found a significantly lower 30-day mortality in the 
MTP group compared to the non-MTP group (Martinez-Calle et al.: 18.1% and 13.0% vs. 30.2%. 
[two MTP groups], p=0.010(8); Johansson et al.: 34% vs. 56%, p=0.02(28)). In contrast, 
McDaniel et al. found no significant difference of the 30-day mortality in the MTP group and 
non-MTP group (50.0% vs. 42.1%, p=0.207).(6) Likewise, the study by Balvers et al. revealed 
no significant difference of the 28-day mortality after the implementation of a MTP (35% vs. 
34%, p=0.801).(10) (Table 3) 
Three studies compared the 24-hour mortality in MTP and non-MTP groups. In two of these 
three studies, the 24-hour mortality was not significantly different between the MTP and non-
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MTP group (McDaniel et al.: 30.8% vs. 15.8%, p=0.155(6); Balvers et al.: 15% vs. 12%, 
p=0.386(10)). On the other hand, Martinez-Calle et al. found a significantly lower 24-hour 
mortality in the MTP group compared to the non-MTP group (0.0% and 1.1% vs. 7.3% [two 
MTP groups], p=0.002).(8) (Table 3) 
Meta-analysis included four studies that reported mortality of MTP and non-MTP groups in non-
trauma patients specifically.(6, 8, 11, 28) Meta-analysis revealed no statistically sigificant effect 
of MTP on the 24-hour mortality rate (OR 0.42, 95%CI 0.01-16.62, p=0.65) and one-month 
mortality (OR 0.56, 95%CI 0.30-1.07, p=0.08). (Figure 2) 
 
Discussion 
The aim of this systematic literature review and meta-analysis was to find scientific evidence for 
the use of MTP in bleeding non-trauma patients. Twelve studies including patients with 
perioperative, gastrointestinal, and obstetrical bleeding, as well as bleeding from vascular 
emergencies, were assessed. (Figure 1) 
Two studies found a significantly lower mortality associated with the introduction of a MTP in 
bleeding non-trauma patients.(8, 28) In two other studies that analyzed mortality before and after 
implementation of a MTP, no statistically significant effect of the introduction of a MTP on 
mortality was found.(6, 10) Furthermore, one study that found a lower mortality in the MTP 
group included patients with ruptured aortic aneurysm only, which is a distinct group of patients 
with a very high mortality and morbidity.(30, 31) On the other hand, meta-analysis including the 
same studies showed a trend towards a lower one-month mortality rate. Based on these results it 
is possible that MTP may lower the mortality rate in bleeding non-trauma patients. Taking into 
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account the small number of studies eligible for inclusion in meta-analysis, more statistical 
power is needed to confirm this hypothesis. 
Another reason for the non-significant effect of MTP on mortality found in the current meta-
analysis may be delayed MTP activation in the studies included. In major trauma patients, severe 
bleeding is anticipated and MTP are readily activated according to clearly defined criteria.(16) In 
non-trauma patients, the onset of bleeding may be more subtle, delaying the activation of MTP. 
Furthermore, well-defined criterial for massive transfusion in non-trauma patients are lacking. 
Martinez et al. report proactive triggering of MTP in only 20% in non-trauma patients. In the 
other 80%, MTP was automatically activated by the blood bank after the transfusion of more 
than 8 PRBC.(8) In the study by McDaniel et al. MTP activation accelerated the delivery of of 
FFP and platelets. However, MTP activation was not associated with improved survival in this 
study.(6)  
Although one of the goals of MTP is to achieve higher plasma and platelets to PRBC transfusion 
ratios, FFP:PRBC and/or PLT:PRBC transfusion ratios did not meet the currently recommended 
ratios of 1:1:1 or 1:1:2(32) in four studies.(8, 9, 11, 29) (Table 2) This finding is surprising, as 
with the introduction of a MTP, predefined ratios of blood products should be available for 
transfusion.(12, 15, 33-35) A possible explantation for the lower than recommended transfusion 
ratios in these studies may be a delayed MTP activation with unbalanced PRBC transfusion prior 
to the activation of the protocol.(8) 
A high rate of MTP overactivation was found in four studies.(4, 6, 7, 9) The identification of 
non-trauma patients that require MTP activation may be challenging as specific criteria are still 
lacking. In trauma patients, on the contrary, there are well established criteria for massive 
transfusion and MTP activation, such as the ACS TQIP Best Practice Guidelines(16), the 
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Assessment of Blood Consumption (ABC) score(36-38), the Trauma Associated Severe 
Hemorrhage (TASH) score(39), the algorithm developped for combat casualty patients by 
McLaughlin and collegues(40), the Revised Assessment of Bleeding and Transfusion (RABT) 
score(41), and the Massive Transfusion Score (MTS)(42). The absence of defined criteria for 
massive transfusion in non-trauma patients most likely explains the high overactivation rate in 
this patient population. 
The study of McDaniel et al. was the only one that analyzed the waste of blood products. An 
increased waste of platelets was found after the introduction of a MTP.(6) The waste of blood 
products associated with MTP could potentially be prevented, as unused blood products may be 
provided to other patients if they are returned promptly to the blood bank.(6) Furthermore, timely 
termination of the MTP once the endpoints of transfusion are achieved may reduce the waste of 
blood products. The ACS TQIP lists several criteria for the termination of MTP, including 
downgrading to goal-directed transfusion if bleeding has been controlled by surgery or 
angioembolization, further resuscitation is futile, and - in patients with no active bleeding - 
laboratory findings indicate adequate blood coagulation.(16) Although the ACS TQIP criteria for 
the termination of MTP were elaborated for trauma patients, they may also be useful in non-
trauma patients. Further studies will need to evaluate the criteria for MTP termination in non-
trauma patients specifically. 
Non-trauma patients included in the current review had many comorbidities, especially from 
cardiovascular origin.(4, 10, 28, 29) (Table 1) Trauma patients are typically younger and have 
less comorbidities than the non-trauma patients included in the current review. Furthermore, 
polytrauma patients may bleed from multiple injuries, whereas bleeding is often localized in non-
trauma patients, e.g. in patients with gastrointestinal bleeding or bleeding during cardio-vascular 
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surgery. Both trauma and non-trauma patients may suffer from profuse bleeding due to 
coagulopathy. However, due to the above-mentioned cardiovascular comorbidities, drug-induced 
coagulopathy is more likely in non-trauma than in trauma patients.(43) When extrapolating 
indications and goals of MTP from trauma to non-trauma patients, the different characteristics of 
these two patient populations need to be considered. 
This systematic literature review and meta-analysis has several limitations. First, all studies were 
retrospective. Second, three studies analyzed mixed cohorts of non-trauma and trauma patients(5, 
10, 29), while others focused on a specific group of patients(11, 26-28). Third, the total number 
of patients that were included in meta-analysis was relatively small, limiting the validity of the 
results. Fourth, the quality of the studies included varied and was poor in some studies. (Table 4) 
Fifth, massive transfusion protocols, including the indication for MTP activation and predefined 
transfusion ratios, differed between the studies included. In order to take into account the 
heterogeneity of the studies included, only studies reporting outcomes of MTP- and non-MTP 
groups in non-trauma patients specifically were included in the quantitative analysis. 
Furthermore, a radom-effects model was chosen for meta-analysis. 
Conclusion 
Based on the current literature review and meta-analysis, there is limited evidence that the 
implementation of MTP may be associated with decreased mortality in non-trauma patients. 
Both, overactivation and an increased waste of blood products have been reported with the 
introduction of MTP. However, patient characteristics, as well as the indication and definition of 
MTP were highly hetergenous in the available studies. Further prospective investigation into this 
topic is warranted. 
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Figures and Tables Legend 
Figure 1. *Records relevant to the topic that were cited in articles identified by the literature 
search 
 
Figure 2. MTP: massive transfusion protocol, CI: confidence interval, M-H: Mantel–Haenszel 
statistics. 
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Table 1. Studies included 
Author,  Journal, Year Study type Study 
size* 
Patient characteristics* Age Indication for MTP 
activation 
MTP/Non-
MTP* 
  (n=)  (Years)   
Dutta et al.,  Am J 
Perinatol, 2017 
Retrospective 
single center 
62 Obstetric: 62 (100) Pre-MTP: 29.9±1.0‡ 
Post-MTP: 32.7±1.2‡ 
Clinical judgement 6/56 
Chay et al., Vox Sang, 
2016 
Retrospective 
multicenter 
434 Major surgery: 130 (30), gastrointestinal bleeding: 109 (25), obstetric: 26 (6), 
trauma: 169 (39) 
- Clinical judgement 434/0 
Martinez-Calle et al., 
Med Intensiva, 2016 
Retrospective 
single center 
304 Oncologic surgery: 88 (28.9), cardiovascular surgery: 105 (34.5), other surgery: 57 
(18.8), non-surgical bleeding: 54 (17.8) 
Pre-MTP: 62 (52-74)+ 
MTP: 62 (50-71)+ 
Replacement of whole blood 
volume in 24h/Replacement 
of 50% of blood volume in 
3h/Blood loss > 1500ml in 
10min/Triggered by blood 
bank if > 8 PRBC used 
208/96 
Wijaya et al., 
Singapore Med J, 2016 
Retrospective 
single center 
46 GIT bleeding: 12 (26.1), ruptured AAA: 3 (6.5), ruptured splenic artery aneurysm: 1 
(2.2), intraoperative bleeding: 1 (2.2), postoperative bleeding: 1 (2.2), trauma: 28 
(60.9) 
55.67±19.36‡ Clinical judgement 46/0 
Balvers et al., J Emerg 
Trauma Shock, 2015 
Retrospective 
single center 
547 Trauma: 48 (8.8), surgery: 348 (63.1), obstetric: 22 (4.0), internal Medicine: 69 
(12.6), other: 60 (11.0) 
Pre-MTP: 65 (51-76)+ 
MTP: 65 (52-73)+ 
SBP <90mmHg with no 
response to fluid 
administration and suspicion 
of massive bleeding 
115/432 
Baumann Kreuziger et 
al., Transfus Med, 
2014 
Retrospective 
single center 
133a Vascular rupture: 23 (18.4), GIT bleeding: 16 (12.8), cardiothoracic surgery: 11 (8.8), 
obstetric: 5 (4.0), thrombosis: 2 (1.6), orthopedic: 1 (0.8), trauma: 62 (49.6), other: 
5 (4.0) 
53±18.6‡ Clinical judgement 125/8 
McDaniel et al., J Am 
Coll Surg, 2013 
Retrospective 
single center 
164 GIT bleeding: 21 (12.8), medical bleeding for other reasons:  6 (3.7), 
postsurgical/procedural complications: 18 (11.0), vascular emergencies: 18 (11.0), 
cerebral hemorrhage: 1 (0.6), trauma: 100 (61.0) 
MTP: 57.9±19.8‡ 
nMTP: 64.6±16.4‡ 
Clinical judgement 52/112 
Sinha et al., Transfus 
Med, 2013 
Retrospective 
single center 
152 Ruptured AAA: 31 (20), cardiac surgery: 12 (8), other surgery: 29 (19),  GIT bleeding: 
23 (15), obstetric: 16 (11), liver transplantation: 4 (3), trauma: 37 (24) 
61 (40-78)+ Clinical judgement 83/69 AC
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Morse et al., Am Surg, 
2012 
Retrospective 
single center 
439 GIT bleeding: 18 (4.1), intraopoerative bleeding: 13 (3.0), obstetric: 5 (1.1), 
ruptured AAA: 1 (0.2), trauma: 402 (91.6) 
37.5±0.74# Clinical judgement 439/0 
Gutierrez et al., Int J of 
Obstet Anesth, 2012 
Retrospective 
single center 
31 Obstetric: 31 (100) 33.5±6.1‡ Clinical judgement 31/0 
Goodnough et al., 
Transfusion, 2011 
Retrospective 
single center 
31 Obstetric: 31 (100) - Emergent need for blood 
products (not further 
specified) 
31/0 
Johansson et al., 
Transfusion, 2007 
Retrospective 
single center 
132 Ruptured AAA: 132 (100) Pre-MTP: 73 (51-84)+ 
MTP: 71 (48-89)+ 
Massive bleeding (not 
further specified) 
50/82 
*Values are numbers (percentages). +Median (IQR). #Mean±SEM. ‡Mean±SD. aIncluding 8 patients that were transfused off-protocol and were not included in the analysis. 
MTP: massive transfusion protocol, PRBC: packed red blood cells, GIT: gastrointestinal tract, AAA: abdominal aortic aneurism, SBP: systolic blood pressure. 
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Table 2. Blood products, transfusion ratios, and overactivation 
Author, Year, 
Journal 
Units transfused per patient Transfusion ratios Over-
activation 
 PRBC FFP Platelets   
Dutta, E. H., et al., 
2017, Am J Perinatol 
Pre-MTP: 6 (5-8)+ 
MTP: 7 (5-9)+ 
p=0.85 
Pre-MTP: 4 (1-5)+ 
MTP: 2 (0-4)+ 
p=0.28 
Pre-MTP: 0 (0.0-0.6)+ 
MTP: 0 (0.0-0.6)+ 
p=0.63 
FFP:PRBC 
Pre-MTP: 0.5 (0.1-0.6)+, MTP: 0.3 (0.0-
0.5)+, p=0.31 
PLT:PRBC 
Pre-MTP: 0.0 (0.0-0.6)+, MTP: 0.0 (0.0-
0.7)+, p=0.42 
- 
Chay et al., 2016, 
Vox Sang 
Range 5-12† Range 4-8† Range 3- 8† 
FFP:PRBC 
Range 0.6-0.8† 
PLT:PRBC 
Range 0.6-0.8† 
- 
Martinez-Calle et 
al., 2016, Med 
Intensiva 
(two MTP groups) 
Pre-MTP: 9 (6)+ 
MTP: 19 (9)+ 
p=0.688 
Pre-MTP: 5 (6)+ 
MTP: 77 (37)+ 
p=0.238 
Pre-MTP: 1 (2)+ 
MTP: 5 (2)+ 
p=0.751 
FFP:PRBC 
Pre-MTP: 0.44 (0.30-0.67)+, MTP: 0.57 
(0.33-0.77)+ and 0.55 (0.33-0.79)+, 
p=0.053 
PLT:PRBC 
Pre-MTP: 0.10 (0.0- 0.15)+, MTP: 0.11 
(0.0-0.18)+ and 0.1 (0.0-0.17)+, p=0.429 
- 
Wijaya et al., 2016, 
Singapore Med J 
- - - 
FFP:PRBC: 0.655±0.192‡ 
PLT:PRBC: 0.141±0.072‡ 
11 (61.1) 
Balvers et al., 2015, 
J Emerg Trauma 
Shock 
Pre-MTP: 8 (6-12)+ 
MTP: 8 (7-13)+ 
p=0.279 
Pre-MTP: 6 (3-9)+ 
MTP: 6 (4-11)+ 
p=0.224 
Pre-MTP: 2 (1-3)+ 
MTP: 2 (0-4)+ 
p=0.139 
PRBC:FFP ≤ 1.1 
Pre-MTP: 70 (37)*, MTP: 168 (47)*, 
p=0.014 
PRBC:PLT ≤ 1.1 
Pre-MTP: 119 (62)*, MTP: 230 (65)*, 
p=0.514 
- 
Baumann Kreuziger 
et al., 2014, 
Transfus Med 
8.7±7.0‡ 6.2±5.7‡ 1.5±1.3‡ 
Plasma:PRBC 
<1:4: 7 (11.1)* 
1:4-1:2: 11 (17.5)* 
1:2-1:1: 37 (58.7)* 
>1:1: 8 (12.7)* 
41 (65) 
McDaniel et al., 
2013, J Am Coll Surg 
Non-MTP: 12.2±9.0‡ 
MTP: 12.6±11.5‡ 
p=0.864 
Non-MTP: 8.9±8.7‡ 
MTP: 9.2±8.0‡ 
p=0.631 
Non-MTP: 6.5±8.6‡ 
MTP: 7.2±6.7‡ 
p=0.183 
FFP:PRBC 
MTP: 0.79:1±0.34:1‡, Non-MTP: 
0.65:1±0.39:1, p=0.282 
PLT:PRBC 
MTP: 0.61:1±0.42:1‡, Non-MTP: 
0.53:1±0.54:1, p=0.476 
14 (53.8) 
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Sinha et al., 2013, 
Transfus Med 
Pre-MTP: 16 (12-20)+ 
MTP: 14 (11-21)+ 
Pre-MTP: 6 (5-10)+ 
MTP: 10 (7-17)+ 
Pre-MTP: 2 (1-3)+ 
MTP: 3 (2-4)+ 
FFP:PRBC 
Pre-MTP: 1:2.4 (1:1.8-1:3.4)+, MTP: 
1:1.4 (1:1.2-1:2.0)+, p<0.001 
PLT:PRBC 
Pre-MTP: 1:10 (1:6.0-1:14.0)+, MTP: 1:6 
(1:4.1-1:8.0)+, p<0.001 
- 
Morse et al., 2012, 
Am Surg 
12.5±2.0# 7.9±1.3# 8.6±1.4# 
PRBC:FFP: 1:2.2±0.3# 
PRBC:PLT: 1:2.3±0.4# 
20 (54) 
Gutierrez et al., 
2012, Int J of Obstet 
Anesth 
3.0 (1.8-7.0)+ 3.0 (1.5-5.5)+ 1.0 (0.0-2.5)+ - - 
Goodnough et al., 
2011, Transfusion 
5.0 (4.0-7.5)+ 2.0 (0.0-4.0)+ 1.0 (0.0-1.0)+ - - 
Johansson et al., 
2007, Transfusion 
OR: no difference 
ICU: Pre-MTP: 6 (0-54)+, 
MTP: 2 (0-30)+, p<0.05 
OR: Pre-MTP: 0 (0-3)+, 
MTP: 4 (2-16)+, p<0.05 
ICU: Pre-MTP: 1 (0-6)+, 
MTP: 0 (0-4)+, p<0.05 
OR: Pre-MTP: 7 (0-46)+, 
MTP: 11 (2-42)+, p<0.05 
ICU: Pre-MTP: 4 (0-32)+, 
MTP: 2 (0-12)+, p<0.05 
- - 
*Numbers (percentage). +Median (IQR). †Median. ‡Mean ± SD. #Mean ± SEM. 
MTP: massive transfusion protocol. PRBC: packed red blood cells. FFP: fresh frozen plasma. PLT: platelets. AAA: abdominal aortic aneurysm. OR: operating room. 
ICU: intensive care unit. 
Overactivation: < 10 units of PRBC transfused for patients with activated MTP. 
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Table 3. 24-hour and one-month mortality 
Author, Year, Journal 24-hour mortality One-month mortality* 
 n (%) n (%) 
Dutta, E. H., et al., 2017, Am J Perinatol 
Pre-MTP: 0 (0) 
MTP: 0 (0) 
Pre-MTP: 0 (0) 
MTP: 0 (0) 
Chay et al., 2016, Vox Sang - - 
Martinez-Calle et al., 2016, Med Intensiva 
Pre-MTP: 7 (7.3) 
MTP:  0 (0.0) and 1 (1.1) (2 MTP groups) 
p=0.002 
Pre-MTP: 29 (30.2) 
MTP: 21 (18.1) and 12 (13.0) (2 MTP groups) 
p=0.010 
Wijaya et al., 2016, Singapore Med J - - 
Balvers et al., 2015, J Emerg Trauma Shock 
Pre-MTP: 23 (12.0) 
MTP: 52 (15.0) 
p=0.386 
Pre-MTP: 65 (34) 
MTP: 124 (35) 
p=0.801 
Baumann Kreuziger et al., 2014, Transfus Med - - 
McDaniel et al., 2013, J Am Coll Surg 
Non-MTP: 6 (15.8) 
MTP: 8 (30.8) 
p=0.155 
Non-MTP: 16 (42.1) 
MTP: 13 (50.0) 
p=0.207 
Sinha et al., 2013, Transfus Med - - 
Morse et al., 2012, Am Surg MTP: 15 (41.0) MTP: 18 (49.0) 
Gutierrez et al., 2012, Int J of Obstet Anesth - - 
Goodnough et al., 2011, Transfusion - - 
Johansson et al., 2007, Transfusion - 
Pre-MTP: 46 (56) 
MTP: 17 (34) 
p=0.02 
(death in OR excluded) 
*Fisher’s exact test, studies that reported mortality in non-trauma patients specifically. 
MTP: massive transfusion protocol, OR: operating room, CI: confidence interval. AC
CE
PT
ED
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
32 
 
Table 4. Quality assessment using the Newcastle-Ottawa Scale for cohort studies 
Author,  Journal, Year Selection Comparability Outcome Total 
 Representative-
ness of the 
exposed cohort 
Selection of the 
non-exposed 
cohort 
Ascertainment of 
exposure 
Demonstration 
that outcome of 
interest was not 
present at start of 
study 
 Assessment of 
outcome 
Follow-up long 
enough for 
outcomes to occur 
Adequacy of 
follow up of 
cohorts 
 
Dutta et al.,  Am J 
Perinatol, 2017 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Chay et al., Vox Sang, 
2016 
✻ ✻ ✻ ✻     4 
Martinez-Calle et al., 
Med Intensiva, 2016 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Wijaya et al., Singapore 
Med J, 2016 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Balvers et al., J Emerg 
Trauma Shock, 2015 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Baumann Kreuziger et 
al., Transfus Med, 2014 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
McDaniel et al., J Am 
Coll Surg, 2013 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Sinha et al., Transfus 
Med, 2013 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Morse et al., Am Surg, 
2012 
✻ ✻ ✻ ✻  ✻ ✻ ✻ 7 
Gutierrez et al., Int J of 
Obstet Anesth, 2012 
✻  ✻ ✻     3 
Goodnough et al., ✻  ✻ ✻     3 AC
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Transfusion, 2011 
Johansson et al., 
Transfusion, 2007 
✻ ✻ ✻ ✻  ✻ ✻  6 
Quality assessment with mortality as outcome. 
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Table 5. PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  1, 2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
2 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
3, 4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
3, 4 AC
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Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
3, 4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
3, 4, Figure 1 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
4 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
4 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
4, 14, 15 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  4, 5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
4, 5 
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Table 5. PRISMA 2009 Checklist (cont.) 
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
5 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
6, Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
6, Table 1 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  6, 7, Table 4 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
10, 11, Table 3, 
Figure 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10, 11, Figure 2 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  4, 5, 14, 15, 
Figure 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
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DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
12, 13, 14 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
14, 15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
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